Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7539 1801

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Report: Pharma and Biotech 2013 in Review

EP Vantage Biggest Launches 2014

                         

 

 

  Download Report

The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company valuations in the US and the opening of the IPO floodgates. The pharma and biotech sector also saw an increase in M&A deal values, buoyant licensing activity and sustained venture capital investment last year, according to EP Vantage's latest report Pharma and Biotech 2013 in Review.

The record-breaking value of new drug approvals was another notable story last year. Although the number of novel medicines to reach the market dipped on 2012, the class of 2013 is forecast to generate $25.4bn in their fifth year on the market - the best performance of the last decade.

Key findings in EP Vantage Pharma and Biotech 2013 in Review:

  • The Nasdaq Biotech Index ended the year 66% higher than its previous peak during the genomics bubble of 2000
  • Combined fifth-year projected sales for drugs approved in 2013 are forecast to hit $25.4bn, the highest in the last decade
  • Of the 33 drugs approved in 2013, eight are forecast to become blockbusters by 2018
  • The average price paid in M&A deals reached $708m last year, the highest since pre-cash levels
  • Venture capital investments in companies developing human therapeutics stabilized on 2012 at $4.5bn

Download Report

Press Release

Related Reports: 

EP Vantage: Medtech 2013 in Review

EP Vantage: Biggest Launches 2014

EP Vantage: A Breakthrough Year for Unmet Diseases

EP Vantage FDA Approval Rates 2013